DRUG · Unmapped registry intervention
ONC-392 low
Find medicine records ·
Find other trials using this name
Clinical trial
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443
Study summary
ClinicalTrials.govONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1, PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
ONC-392 high
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
lutetium Lu 177 vipivotide tetraxetan
Normalized identity: lutetium Lu 177 vipivotide tetraxetan View linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Interventions
Sponsors & collaborators
OncoC4, Inc.lead sponsor
Prostate Cancer Clinical Trials Consortiumcollaborator
Mapped research locations
New YorkNew York, United States2DallasTexas, United States1BaltimoreMaryland, United States1AtlantaGeorgia, United States1ColumbusOhio, United States1TampaFlorida, United States1PortlandOregon, United States1DurhamNorth Carolina, United States1AuroraColorado, United States1OmahaNebraska, United States1Chapel HillNorth Carolina, United States1SacramentoCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05682443 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.